World’s First Personalized Ovarian Cancer Vaccine Trial Recruits Patients at UConn Health

World’s First Personalized Ovarian Cancer Vaccine Trial Recruits Patients at UConn Health
The University of Connecticut Health Center (UConn Health) is recruiting ovarian cancer patients for the world’s first clinical trial testing a personalized genomics-driven vaccine (NCT02933073). The vaccine, called OncoImmunome, targets women with advanced stages of the disease to prevent its relapse. The vaccine boosts a patient’s immune response, killing ovarian cancer cells should they reappear. The U.S. Food and

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *